Within- and Between-Family Validation of Nine Polygenic Risk Scores for IVF (mynucleus.com)

Nucleus Labs unveiled Origin, a family of nine polygenic risk scores (PRSs) designed for use with embryonic DNA in IVF, claiming state-of-the-art accuracy that “surpasses all published benchmarks” for age-related conditions such as Alzheimer’s, various cancers, and diabetes. The company says the models were trained and validated on data from millions of people across diverse ancestries and have undergone both within‑family and between‑family validation—an important methodological step that reduces confounding from population structure and shared environment and strengthens causal interpretation of genetic risk differences between embryos. Technically notable is that Origin’s model weights are being released openly, enabling independent replication, benchmarking, and further research by the community. If the performance claims hold up under external scrutiny, these PRSs could materially change embryo selection practice by extending selection criteria beyond single‑gene disorders to quantitative disease risk profiles. The announcement raises consequential scientific and ethical questions about clinical utility, informed consent, equity, and regulation; open weights and rigorous validation should accelerate both technical follow‑up and necessary debate within the AI/ML, genetics, and reproductive-health communities.